Statistical controversies in clinical research: an initial evaluation of a surrogate end point using a single randomized clinical trial and the Prentice criteria

被引:10
作者
Heller, G. [1 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10017 USA
关键词
equivalence test; Prentice criteria; randomized clinical trial; surrogate end point; RESISTANT PROSTATE-CANCER; CIRCULATING TUMOR-CELLS; VALIDATION;
D O I
10.1093/annonc/mdv333
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Surrogate end point research has grown in recent years with the increasing development and usage of biomarkers in clinical research. Surrogacy analysis is derived through randomized clinical trial data and it is carried out at the individual level and at the trial level. A common surrogate analysis at the individual level is the application of the Prentice criteria. An approach for the evaluation of the Prentice criteria is discussed, with a focus on its most difficult component, the determination of whether the treatment effect is captured by the surrogate. An interpretation of this criterion is illustrated using data from a randomized clinical trial in prostate cancer.
引用
收藏
页码:2012 / 2016
页数:5
相关论文
共 14 条
[1]   Prentice's approach and the meta-analytic paradigm: A reflection on the role of statistics in the evaluation of surrogate endpoints [J].
Alonso, A ;
Molenberghs, G ;
Burzykowski, T ;
Renard, D ;
Geys, H ;
Shkedy, Z ;
Tibaldi, F ;
Abrahantes, JC ;
Buyse, M .
BIOMETRICS, 2004, 60 (03) :724-728
[2]   STATISTICS NOTES - ABSENCE OF EVIDENCE IS NOT EVIDENCE OF ABSENCE [J].
ALTMAN, DG ;
BLAND, JM .
BRITISH MEDICAL JOURNAL, 1995, 311 (7003) :485-485
[3]  
Buyse M, 2000, Biostatistics, V1, P49, DOI 10.1093/biostatistics/1.1.49
[4]   Circulating Tumor Cells as Biomarkers in Prostate Cancer [J].
Danila, Daniel C. ;
Fleisher, Martin ;
Scher, Howard I. .
CLINICAL CANCER RESEARCH, 2011, 17 (12) :3903-3912
[5]   Surrogate endpoints and FDA's accelerated approval process [J].
Fleming, TR .
HEALTH AFFAIRS, 2005, 24 (01) :67-78
[6]   STATISTICAL VALIDATION OF INTERMEDIATE END-POINTS FOR CHRONIC DISEASES [J].
FREEDMAN, LS ;
GRAUBARD, BI ;
SCHATZKIN, A .
STATISTICS IN MEDICINE, 1992, 11 (02) :167-178
[7]  
Molenberghs G, 2005, STAT BIOL HEALTH, P67
[8]   Quantification of the prentice criteria for surrogate endpoints [J].
O'Quigley, J ;
Flandre, P .
BIOMETRICS, 2006, 62 (01) :297-300
[9]   Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16 [J].
Petrylak, DP ;
Ankerst, DP ;
Jiang, CS ;
Tangen, CM ;
Hussain, MHA ;
Lara, PN ;
Jones, JA ;
Taplin, ME ;
Burch, PA ;
Kohli, M ;
Benson, MC ;
Small, EJ ;
Raghavan, D ;
Crawford, ED .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2006, 98 (08) :516-521
[10]   SURROGATE ENDPOINTS IN CLINICAL-TRIALS - DEFINITION AND OPERATIONAL CRITERIA [J].
PRENTICE, RL .
STATISTICS IN MEDICINE, 1989, 8 (04) :431-440